When President Donald J. Trump unveiled his “Trump RX” initiative, few expected it would immediately shake up America’s booming GLP-1 drug market. But the administration’s recent pricing deals with Eli Lilly and Novo Nordisk — the makers of Ozempic, Wegovy, Mounjaro, and Zepbound — mark a seismic shift in how weight-loss and diabetes medications are priced, distributed, and prescribed across the United States.